The Role of Uron and Chlorobenzene Derivatives, as Potential Endocrine Disrupting Compounds, in the Secretion of ACTH and PRL

Krisztian Sepp, Anna M. Laszlo, Zsolt Molnar, Andrea Serester, Tunde Alapi, Marta Galfi, Zsuzsanna Valkusz, and Marianna Radacs

1First Department of Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary
2Department of Biometrics and Agricultural Informatics, Faculty of Horticultural Science, Szent István University, Budapest, Hungary
3Department of Environmental Biology and Education, Institute of Environmental and Technological Sciences, Juhász Gyula Faculty of Education, University of Szeged, Szeged, Hungary
4Department of Inorganic and Analytical Chemistry, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary

Correspondence should be addressed to Krisztian Sepp; sepp.krisztian@med.u-szeged.hu

Received 7 March 2018; Revised 22 April 2018; Accepted 3 May 2018; Published 29 May 2018

1. Introduction

Chemical agents (e.g., halogenated hydrocarbons and uron herbicides [1–3]) which pollute the environment represent a serious concern for environmental health and may be regarded as endocrine-disrupting compounds (EDCs), which influence the regulation of human homeostasis. We aimed to investigate the effect of EDC urons (phenuron: PU, monuron: MU, and diuron: DU) and chlorobenzenes on the basal release of the adrenocorticotrophic hormone (ACTH), which is a part of the adenohypophysis-adrenocortical axis. Hormone secretion in the presence of EDC was studied in two cell types: normal adenohypophysis cells (AdH) and cells of prolactinomas (PRLOMA). PRLOMA was induced in female Wistar rats by subcutaneously injecting them with estrone acetate for 6 months. AdH and PRLOMA were separated from treated and untreated experimental animals, dissociated enzymatically and mechanically in order to create monolayer cell cultures, which served as an experimental in vitro model. We investigated the effects of ED agents separately and in combination on ACTH and prolactin (PRL) release through the hypothalamic-adrenal axis. Hormone determination was carried out by the luminescent immunoassay and the radioimmunoassay methods. Our results showed that (1) uron agents separately did not change ACTH and PRL release in AdH culture; (2) ACTH secretion in arginine vasopressin-(AVP-) activated AdH cells was significantly increased by EDC treatment; (3) ED agents increased the basal hormone release (ACTH, PRL) in PRLOMA cells; and (4) EDC exposure increased ACTH release in AVP-activated PRLOMA cells. We conclude that the herbicides PU, MU, and DU carry EDC effects and show human toxicity potential.
adaptation potential (algorithmic networks characterizing the local properties of the living system [18]). In human homeostasis, hormones are the creative elements of the neuroendocrine regulation [19, 20]. Human neuroendocrine regulation can be interpreted as a network of open, dynamic biological systems [21] in the outlined context. Biological cycles that can be described with the “AND” function are those essential for life (e.g., human hypothalamus-adrenohypophysis-adenal cortex axis functional disorder) [22]. The “OR” function-related control systems are not essential at the organizational level of the given individual (e.g., PRL); life functions can be maintained in their absence. The disturbance of the healthy (control) processes of the “OR” cycle will affect the “AND” cycles. Chronic changing of the “OR” cycle may lead to structural disturbance, for example, cellular proliferation, which is sustained by continuous feedback information [23].

Hormones are the creative elements of the "AND" function. The adenohypophysis-adrenal cortex axes (case of prolactinoma, a signiﬁcant pathophysiological role is attributed to the estrogenic effect [29]).

2. Materials and Methods

2.1. Experimental Animals. Certified healthy female rats were used in our experiments (Wistar strains weighing 120–250 g, 4–6 weeks old at the onset of the study) (Charles River, Isaszeg, Hungary). During the experimental period, animals were kept in a controlled (55–65% relative humidity, 22 ± 2°C air temperature), automated diurnal environment (12 h daytime, 12 h night illumination cycles) in 32 × 40 × 18 cm cages (5 animals/cage). The diet required for experimental animals (CRLT/N, Charles River, Hungary) and drinking water were available ad libitum. The animals involved in the study were treated in accordance with Gov. Ordinance Number 40/2013 (II. 14.) on animal experiments.

2.2. Induced Prolactinoma and In Vitro Experimental Models. The PRLOMA models were made from Wistar rats (n = 20) which were subcutaneously injected with estrone acetate for 6 months (CAS registration number 901-93-9, Sigma, Germany, 150 μg/kg/week) [44]. After the pentobarbital (4.5 mg/kg, Nembutal, Abbott, USA) anesthesia, the animals were decapitated and AdH was separated; the tissue was enzymatically (trypsin: Sigma, Germany) + 20% fetal calf serum (FCS, Sigma, Germany) + 1.0 IU/ml penicillin + streptomycin (Sigma, Germany). Then, they were placed into surface-treated (5% collagen) 24-well plastic culture vessels (Nunc, Germany) and put in a thermostat (temperature = 37°C, pCO₂: 5%). Cell cultures were washed every 3 days after adherence until they became confluent.
2.3. Experimental Protocol. Time and dose kinetic assays, determining the appropriate arrangements, were performed on standardized AdH and PRLoma in vitro cultures. In the present study, AdH and PRLoma cell cultures were first treated for 60 minutes with chlorobenzene (dClB = 0.1 ng/ml; chlorobenzene mix (mClB) = 0.1 ng/ml; hexachlorobenzene and 1,2,4-trichlorobenzene 1:1) and with urons (PU: 10⁻⁶ M, MU: 10⁻⁶ M, DU: 10⁻⁶ M). At the end of the EDC treatment, samples were obtained from the supernatant media of the cell cultures for the determination of ACTH and PRL hormones. When studying the ACTH-mediated role of EDC agents in the hypothysis/adrenal cortex regulation, the EDC agents were coadministered with (10⁻⁶ M) AVP and after the 60-minute treatment period, samples were taken from the supernatant media of both AdH and PRLoma, in the regulation cycle of AVP/B feedback studies in Figures 1 and 2.

EDCs were added together with B. AVP was administered after a 20-minute pretreatment with EDC + B, and at the end of the treatment period, the supernatant media were sampled. In order to follow PRL hormone release, AdH and PRLoma cell cultures were individually treated with ED agents for 60 minutes. Next, the supernatant media were used to measure PRL.

2.4. Hormone Assays. PRL assay was performed by radioimmunoassay from samples obtained according to the experimental protocol [44]. Determination of ACTH from samples was carried out by the luminescent immunoassay method, using the apparatus of the Endocrinology Unit, First Dept. of Internal Medicine, Faculty of Medicine, University of Szeged (Immulfite 2000, Siemens Healthcare Diagnostic, Deerfield, IL, USA and DPC kit/2KAC-02, Euro DPC Ltd., Glyn Rhonwy, United Kingdom). The protein content of the samples was determined using a modified Lowry method [45] and Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, USA).

2.5. Statistical Analysis. Measurements (n = 8 – 12 per group on 24 lots: pooled samples on AdH cell cultures) of ACTH and PRL hormone release by disease (PRLoma versus normal AdH) in various EDC groups (control, dClB, mClB, PU, MU, and DU) by regulation (basal, +AVP, +B, +B+AVP, and +AVP+B) were compared using mixed models in the 5 regulation phases, using disease and regulation as fixed effects and random intercept for the lots. For ACTH data, a mixed model was applied with disease, EDC, and regulation (only basal, +AVP, +B, +B +AVP, and +AVP+B) as fixed factors and random intercept for the lots. For PRL measurements, a mixed model was applied with disease and EDC as fixed factors and random intercept for the lots for basal regulation data. In the analysis models, the reference group was the normal (healthy AdH), control (no EDC treatment), and basal (no regulation) group. Restricted maximum likelihood estimation and Kenward-Roger method for adjusting the degrees of freedom were applied in all models with unstructured covariance matrix. Pairwise comparisons were estimated by least squares means using Sidak p value adjustment. Model residuals were displayed on quantile-quantile plots to check normality assumptions. Statistical analyses were performed in SAS (version 9.3 SAS Institute Inc., Cary, NC, USA), where p values of <0.05 were considered to indicate statistical significance [48].

3. Results

Figure 3 shows the effect of various ED compounds (dClB, mClB, PU, MU, and DU) on ACTH release in AdH cultures...
in the following cases: basal, AVP activated (+AVP), and the corticosterone-inhibited AVP activation (+B+AVP) in AdH cultures. It can be seen that ACTH release was not altered by ED agents (mean level ± SEM (pg ACTH/mg protein)): dClB 1567.91 ± 3.09; mClB 1585.33 ± 2.72; PU 1533.67 ± 2.52; MU 1553.17 ± 3.40; and DU 1566.33 ± 2.30) compared to the control group (1528.25 ± 6.14 pg ACTH/mg protein).

In the AVP-activated samples, ACTH release showed a significant increase compared to the control group for each ED (mean level ± SEM (pg ACTH/mg protein): control 10,220.88 ± 20.36; dClB 14,430.08 ± 3.01; mClB 14,488.90 ± 3.57; PU 11,845.67 ± 7.02; MU 13,008.25 ± 10.18; and DU 13,658.75 ± 15.83). In the case of regulatory effects (+B +AVP-feedback), large deviations could not be detected in the presence of EDC (mean level ± SEM (pg ACTH/mg protein): control 1524.67 ± 3.46; dClB 1542.00 ± 1.22; mClB 1566.92 ± 2.40; PU 1540.08 ± 2.86; MU 1560.08 ± 1.88; and DU 1578.08 ± 1.26).

Figure 4 shows the effects of dClB, mClB, PU, MU, and DU on ACTH release in PRLOMA cultures in the following cases: basal, AVP activation (+AVP), and corticosterone-inhibited AVP activation (+B+AVP). It can be seen that ED agents modulate ACTH release compared to the control of the basal group (2193.64 ± 1.92 pg ACTH/mg protein): dClB: 2624.30 ± 7.60 pg ACTH/mg protein; mClB: 2956.08 ± 4.71 pg ACTH/mg protein; PU: 2427.33 ± 6.08 pg ACTH/mg protein; MU: 2535.17 ± 5.14 pg ACTH/mg protein; and DU: 2705.33 ± 4.63 pg ACTH/mg protein. AVP-activated ACTH release of PRLOMA cultures shows a significant increase for each ED compound used (mean level ± SEM (pg ACTH/mg protein): control 12,674.50 ± 7.23; dClB 14,620.58 ± 5.61; mClB 14,830.50 ± 7.42; PU 13,129.67 ± 6.06; MU 14,954.17 ± 11.22; and DU 15,197.58 ± 4.99). EDC effects were detected in the regulation model (+B+AVP-feedback) (mean level ± SEM (pg ACTH/mg protein): control 2195.50 ± 4.69; dClB 2579.42 ± 3.98; mClB 2513.00 ± 2.94; PU 2421.00 ± 2.28; MU 2553.83 ± 7.87; and DU 2690.42 ± 4.14).

Figure 5 shows the PRL release in AdH cultures in the presence of the ED compounds tested. It can be seen that the ED compounds did not trigger relevant differences in PRL release (mean level ± SEM (ng PRL/mg protein): control: 7.13 ± 0.04; dClB 7.28 ± 0.03; mClB 7.26 ± 0.01; PU 7.12 ± 0.02; MU 7.02 ± 0.02; and DU 7.14 ± 0.01).
4. Discussion and Conclusions

We have studied the effects of PU, MU, DU, dClB, and mClB as potential environmental factors, on the basal release of ACTH (Figure 3) (creative element: mobile network junction [49]), which plays a role in the essential functioning of the AdH/AC axis [30] (interpreted in the human homeostasis [49]), which plays a role in the essential functioning of the ACTH (Figure 3) (creative element: mobile network junction). We have studied the effects of the applied compounds showed a significant stimulating effect (dClB: 22.47 ± 0.03; mClB: 23.17 ± 0.02; PU: 19.82 ± 0.01; MU: 21.50 ± 0.02; and DU: 22.41 ± 0.02 ng PRL/mg protein) on the release of PRL compared to that of the control (17.14 ± 0.02 ng PRL/mg protein) in PRLOMA cultures.

Figure 6 shows the PRL release of rat PRLOMA cultures in the presence of ED chemical agents as described in the experimental protocol. All the examined compounds showed a significant stimulating effect (dClB: 22.47 ± 0.03; mClB: 23.17 ± 0.02; PU: 19.82 ± 0.01; MU: 21.50 ± 0.02; and DU: 22.41 ± 0.02 ng PRL/mg protein) on the release of PRL compared to that of the control (17.14 ± 0.02 ng PRL/mg protein) in PRLOMA cultures.

**Figure 6:** Effects of EDC on PRL release in rat PRLOMA cultures, *in vitro*. Mean (PRL/prolactin/level) ± SEM. The mean and SEM are calculated from n = 12. Abbreviations: dClB = 1,4-dichlorobenzene: 0.1 ng/ml; mClB = chlorobenzene mix: 0.1 ng/ml; PU = phenuron: 10⁻⁶ M; MU = monuron: 10⁻⁶ M; DU = diuron: 10⁻⁶ M. All EDC groups differ significantly from the control (p < 0.001) for basal release.

Figure 6 shows the PRL release of rat PRLOMA cells (Figure 4) in the basal group. PRL release can be increased by enhancing peripheral estrogen levels, which can be the "OR" cycle in connection to ACTH release. In our work, we modeled a homeostatic regulatory neuroendocrine network both under normal regulation (AdH model) and under a neuroendocrine disturbance (+ER). (First, cell cycle change was induced via autoregulatory cell dysfunction [29]). In the PRLOMA cells that were already altered by the control cycle, the level of not only PRL (Figure 6), but also ACTH increased (Figure 4). The events of the neuroendocrine regulatory cycles in our investigation suggest that the outlined mechanisms can be regarded as homeostatic biological network elements [50].

The AVP-activated ACTH hormone secretion of AdH cells was significantly increased by all ED compounds used when compared to the control (Figure 3, +AVP group). ED agents caused increased ACTH release in the AVP-activated PRLMA cells as well (Figure 4, +AVP group). It is well known that in biological complexities (biological networks), regulations appear as the resultants of activating and inhibiting functions [51]. Both in the normal AdH and PRLMA cell types, the negative feedback effect of corticosterone was modeled by the inhibition of AVP-activated ACTH release [52]. Figure 3 demonstrates that AdH cells were able to maintain their inhibitory functions despite a treatment with EDC (Figure 3, +B+AVP group). Thus, the adaptive potential of healthy AdH cells in cases of chemical environmental load modeled by EDC remained reversibly regulated. The regulation of PRLOMA cells was incomplete in the presence of EDC (Figure 4, +B+AVP group); although the inhibitory effect of corticosterone on ACTH secretion is also present in PRLOMA, the maintenance of this effect is strongly disrupted by ED compounds (Figure 4). In this context, the results can be interpreted as an environmental disruption leading to irreversible processes. The presence of ED compounds enhanced the already overexpressed ACTH secretion in PRLOMA cells (Figure 4), which was further increased by AVP activation. Therefore, it can be assumed that both the structure and the endocrine cell function of PRLOMA were damaged [53]. Due to the role ACTH plays in essential life functions, this result may have significance in the environmental exposition of prolactinoma patients and in the development of adaptational potential disorders in healthy individuals [54], as ACTH regulation is present in human adaptation as an open dynamic requirement, which is modeled as an "AND" logical function algorithm. Our results show that PRL secretion in normal AdH cells was not influenced by EDC in the applied experimental system (Figure 5). However, the already elevated PRL secretion of PRLOMA cells was further enhanced by EDC (Figure 6).

HTP is defined in relation to dClB with a standard approach [43] and uniform risk assessment. The authors wished to provide an opportunity for comparison by following dClB effects too. Accordingly, uron/dClB relations were determined in AdH and PRLOMA cells. Our results show that the EDC classification of the examined uron compounds strongly approximates the effects of dClB in an AdH model (Figures 3 and 5). However, basal ACTH release of PRLOMA is more effective in the presence of DU (uron/dClB = 0.97–0.99) than dClB (+DU/dClB = 1.05). In baseline PRL secretion, the uron effects on AdH cells approximated those of dClB (uron/dClB: 0.96–0.98). In the case of PRLOMA, the EDC effects of the investigated uron compounds on PRL secretion approximated those of dClB (uron/dClB: 0.96–0.98). However, in the case of AVP-activated ACTH release in the PRLOMA model, dClB effect was exceeded by the agents MU and DU (PRLOMA: +AVP + MU+/+AVP + dClB = 1.02; PRLOMA: +AVP + DU+/+AVP + dClB = 1.03).

The HTP values of PRLOMA can be interpreted with double risk classification according to our present study, because when the doses of ED compounds exceed those necessary for irreversible effects (such as suspension of corticosterone inhibition), regulatory dysfunctions may present difficult-to-treat disease processes.
It can be seen from the above how important researching human homeostatic network disorders is when one wishes to evaluate the health consequences of environmental factors.

**Data Availability**

Requests for data will be considered by the corresponding author.

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**Acknowledgments**

This research was supported by the European Union and the State of Hungary, cofinanced by the European Social Fund in the framework of TÁMOP-4.2.4.A/2-11/1-2012-0001 “National Excellence Program,” TÁMOP-4.2.6-15-1-2015-0002, EFOP-3.6.1-16-2016-00008, and EFOP-3.4.3-16-2016-00014.

**References**

[1] M. Gavrilescu, K. Demnerová, J. Aamand, S. Agathos, and F. Fava, “Emerging pollutants in the environment: present and future challenges in biomonitoring, ecological risks and bioremediation,” *New Biotechnology*, vol. 32, no. 1, pp. 147–156, 2015.

[2] J. L. Barber, A. J. Sweetman, D. van Wijk, and K. C. Jones, “Hexachlorobenzene in the global environment: emissions, levels, distribution, trends and processes,” *Science of the Total Environment*, vol. 349, no. 1–3, pp. 1–44, 2005.

[3] G. Holmes, “Australia’s pesticide environmental risk assessment failure: the case of diuron and sugarcane,” *Marine Pollution Bulletin*, vol. 88, no. 1-2, pp. 7–13, 2014.

[4] A. Bergman, J. J. Heindel, S. Jobling, K. A. Kidd, and R. T. Zoeller, *State of the Science of Endocrine Disrupting Chemicals - 2012: An Assessment of the State of the Science of Endocrine Disruptors Prepared by a Group of Experts for the United Nations Environment Programme (UNEP) and WHO*, United Nations Environment Programme and the World Health Organization, 2013.

[5] W. H. Goodson III, L. Lowe, D. O. Carpenter et al., “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead,” *Carcinogenesis*, vol. 36, Supplement 1, pp. S254–S296, 2015.

[6] U. Rajamani, A. R. Gross, C. Ocampo, A. M. Andres, R. A. Gottlieb, and D. Sareen, “Endocrine disruptors induce perturbations in endoplasmic reticulum and mitochondria of human pluripotent stem cell derivatives,” *Nature Communications*, vol. 8, no. 1, p. 219, 2017.

[7] A. P. Santos-Silva, M. N. Andrade, P. Pereira-Rodrigues et al., “Frontiers in endocrine disruption: impacts of organotin on the hypothalamus-pituitary-thyroid axis,” *Molecular and Cellular Endocrinology*, vol. 460, pp. 246–257, 2018.

[8] T. T. Schug, A. Janesick, B. Blumberg, and J. J. Heindel, “Endocrine disrupting chemicals and disease susceptibility,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 127, no. 3–5, pp. 204–215, 2011.

[9] J. A. McLachlan, “Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals,” *Endocrine Reviews*, vol. 22, no. 3, pp. 319–341, 2001.

[10] A. Mokarizadeh, M. R. Faryabi, M. A. Rezvanfar, and M. Abdollahi, “A comprehensive review of pesticides and the immune dysregulation: mechanisms, evidence and consequences,” *Toxicology Mechanisms and Methods*, vol. 25, no. 4, pp. 258–278, 2015.

[11] A. Nadal, I. Quesada, E. Tuduri, R. Nogueiras, and P. Alonso-Magdalena, “Endocrine-disrupting chemicals and the regulation of energy balance,” *Nature Reviews Endocrinology*, vol. 13, no. 9, pp. 536–546, 2017.

[12] M. Preciados, C. Yoo, and D. Roy, “Estrogenic endocrine disrupting chemicals influencing NRFl regulated gene networks in the development of complex human brain networks,” *International Journal of Molecular Sciences*, vol. 17, no. 12, 2016.

[13] C. López-Otin, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” *Cell*, vol. 153, no. 6, pp. 1194–1217, 2013.

[14] J. M. Vicencio, L. Galluzzi, N. Tajeddine et al., “Senescence, apoptosis or autophagy? When a damaged cell must decide its path—a mini-review,” *Gerontology*, vol. 54, no. 2, pp. 92–99, 2008.

[15] L. E. Brace, S. C. Vose, K. Stanya et al., “Increased oxidative phosphorylation in response to acute and chronic DNA damage,” *npj Aging and Mechanisms of Disease*, vol. 2, no. 1, p. 16022, 2016.

[16] Z. Kasanova, D. Hernaas, T. Vaessen et al., “Early-life stress affects stress-related prefrontal dopamine activity in healthy adults, but not in individuals with psychiatric disorder,” *PLoS One*, vol. 11, no. 3, article e0150746, 2016.

[17] T. Veithmans, D. Klimov, and D. Thirumalai, “Protein folding kinetics: timescales, pathways and energy landscapes in terms of sequence-dependent properties,” *Folding and Design*, vol. 2, no. 1, pp. 1–22, 1997.

[18] S. Maslov and K. Sneppen, “Specificity and stability in topology of protein networks,” *Science*, vol. 296, no. 5569, pp. 910–913, 2002.

[19] G. Kotronoulas, A. Stamatakis, and F. Stylianopoulou, “Hormones, hormonal agents, and neuropeptides involved in the neuroendocrine regulation of sleep in humans,” *Hormones*, vol. 8, no. 4, pp. 232–248, 2009.

[20] M. P. Cornejo, S. T. Hentges, M. Maliqueo, H. Coirini, D. Becu-Villalobos, and C. F. Elias, “Topological changes in protein networks in the development of complex human brain diseases,” *Toxicology Mechanisms and Methods*, vol. 153, no. 6, pp. 546, 2017.

[21] C. B. Nemero, “Endocrine-disrupting chemicals and the regulation of energy balance,” *Hormones*, vol. 460, pp. 246–257, 2015.

[23] R. S. Wang, A. Saadatpour, and R. Albert, “Boolean model-}

[24] F. Orton, I. Lutz, W. Kloas, and E. J. Routledge, “Endocrine disrupting effects of herbicides and pentachlorophenol: in vitro and in vivo evidence,” *Environmental Science & Technology*, vol. 43, no. 6, pp. 2144–2150, 2009.
[25] Z. Valkusz, G. Nagyéri, M. Radács et al., “Further analysis of behavioral and endocrine consequences of chronic exposure of male Wistar rats to subtoxic doses of endocrine disruptor chlorobenzenes,” Physiology & Behavior, vol. 103, no. 5, pp. 421–430, 2011.

[26] M. A. Oturan, M. C. Edelahi, N. Oturan, K. El kacemi, and J. J. Aaron, “Kinetics of oxidative degradation/mineralization pathways of the phenylurea herbicides diuron, monuron and fenuron in water during application of the electro-Fenton process,” Applied Catalysis B: Environmental, vol. 97, no. 1-2, pp. 82–89, 2010.

[27] H. Motejlová and V. Koci, “Application of 1,4-dichlorobenzene as a reference substance in the LCA methodology (life cycle assessment),” Acta Environmetalica Universitatis Comenianae (Bratislava), vol. 19, pp. 243–246, 2011.

[28] E. R. De Kloet, M. Joels, and F. Holsboer, “Stress and the brain: from adaptation to disease,” Nature Reviews Neuroscience, vol. 6, no. 6, pp. 463–475, 2005.

[29] D. K. Sarkar, “Genesis of prolactinomas: studies using estrogen-treated animals,” Frontiers of Hormone Research, vol. 35, pp. 32–49, 2006.

[30] Z. Molnár, R. Pálföldi, A. László et al., “Effects of chronic and subtoxic chlorobenzenes on adrenocorticotropic hormone release,” Journal of Environmental Sciences, vol. 34, pp. 165–170, 2015.

[31] J. Liu, “Phenylurea herbicides,” in Hayes’ Handbook of Pesticide Toxicology, R. Krieger, Ed., pp. 1725–1731, Academic Press, San Diego, CA, USA, 3rd edition, 2010.

[32] C. Federico, M. Pappalardo, G. C. Loetta, Z. Minniti, V. Librando, and S. Saccone, “Phenylurea herbicides: chemical properties and genotoxic effects,” in Handbook on Herbicides, D. Kobayashi and E. Watanabe, Eds., pp. 111–132, Hauppauge: Nova Science Publishers, 2014.

[33] J. Lintelmann, A. Katayama, N. Kurihara, L. Shore, and A. Wenzel, “Endocrine disruptors in the environment (IUPAC technical report),” Pure and Applied Chemistry, vol. 75, no. 5, pp. 631–681, 2003.

[34] K. A. Lewis, J. Tzilivakis, D. J. Warner, and A. Green, “An international database for pesticide risk assessments and management,” Human and Ecological Risk Assessment: An International Journal, vol. 22, no. 4, pp. 1050–1064, 2016.

[35] W. Minf, A. I. H. Hassine, A. Bouaziz, A. Bartegi, O. Thomas, and B. Roig, “Effect of endocrine disruptor pesticides: a review,” International Journal of Environmental Research and Public Health, vol. 8, no. 6, pp. 2265–2303, 2011.

[36] H. Kojima, E. Katsura, S. Takeuchi, K. Niiyama, and K. Kobayashi, “Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells,” Environmental Health Perspectives, vol. 112, no. 5, pp. 524–531, 2004.

[37] M. Morita, “Chlorinated benzenes in the environment,” Ecotoxicology and Environmental Safety, vol. 1, no. 1, pp. 1–6, 1977.

[38] D. Mackay, W. Y. Shiu, K. C. Ma, and S. C. Lee, Handbook of Physical-Chemical Properties and Environmental Fate for Organic Chemicals, CRC Press, Taylor & Francis, Boca Raton, FL, USA, 2nd edition, 2006.

[39] National Toxicology Program, “Toxicology and carcinogenesis studies of 1,4-dichlorobenzene (CAS no. 106-46-7) in F344/N rats and B6C3F1 mice (gavage studies),” National Toxicology Program Technical Report Series, vol. 319, pp. 1–198, 1987.

[40] A. S. Randi, C. Cocca, V. Carbone et al., “Hexachlorobenzene is a tumor co-carcinogen and induces alterations in insulin-growth factors signaling pathway in the rat mammary gland,” Toxicological Sciences, vol. 89, no. 1, pp. 83–92, 2006.

[41] J. L. Ralph, M. C. Orgebin-Crist, J. J. Lareyre, and C. C. Nelson, “Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene,” Environmental Health Perspectives, vol. 111, no. 4, pp. 461–466, 2003.

[42] C. den Besten, J. J. R. M. Vet, H. T. Besselink et al., “The liver, kidney, and thyroid toxicity of chlorinated benzenes,” Toxicology and Applied Pharmacology, vol. 111, no. 1, pp. 69–81, 1991.

[43] International Standard ISO 14044, “Environmental management. Life cycle assessment. Requirements and guidelines,” International Organization for Standardization, 2006.

[44] Z. Molnár, R. Pálföldi, A. László et al., “The effects of hypokalemia on the hormone exocytosis in adrenohypophysis and prolactinoma cell culture model systems,” Experimental and Clinical Endocrinology & Diabetes, vol. 122, no. 10, pp. 575–581, 2014.

[45] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951.

[46] H. Brown and R. Prescott, Applied Mixed Models in Medicine, Edinburgh: John Wiley & Sons, 2nd edition, 2006.

[47] J. Singer and J. Willett, Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence, Oxford University Press, New York, NY, USA, 2003.

[48] SAS, SAS/STAT 9.3 User’s Guide, Cary: SAS Institute Inc., 2011.

[49] F. L. Strand, K. J. Rose, J. A. King, A. C. Segarra, and L. A. Zuccarelli, “ACTH modulation of nerve development and regeneration,” Progress in Neurobiology, vol. 33, no. 1, pp. 45–85, 1989.

[50] A. Gądek-Michalska, J. Spyrka, P. Rachwalska, J. Tadeusz, and J. Bugajski, “Influence of chronic stress on brain corticosteroid receptors and HPA axis activity,” Pharmacological Reports, vol. 65, no. 5, pp. 1163–1175, 2013.

[51] J. A. McLachlan, “Environmental signaling from environmental estrogens to endocrine-disrupting chemicals and beyond,” Andrology, vol. 4, no. 4, pp. 684–694, 2016.

[52] N. Jasnic, J. Djordjevic, P. Vujovic, I. Lakic, S. Djurasevic, and G. Cvijic, “The effect of vasopressin 1b receptor (V1bR) blockade on HPA axis activity in rats exposed to acute heat stress,” Journal of Experimental Biology, vol. 216, no. 12, pp. 2302–2307, 2013.

[53] M. C. Oh and M. K. Aghi, “Dopamine agonist-resistant prolactinomas,” Journal of Neurosurgery, vol. 114, no. 5, pp. 1369–1379, 2011.

[54] R. L. Spencer and T. Deak, “A users guide to HPA axis research,” Physiology and Behavior, vol. 178, pp. 43–65, 2017.